Immunosuppressive therapies for inflammatory bowel disease.
Inflammatory bowel disease (IBD) is comprised of Crohn's disease and ulcerative colitis, both chronic inflammatory intestinal disorders of unknown etiology characterized by a waxing and waning clinical course. For many years, the drug therapy was limited to sulfasalazine and related aminosalicylates, corticosteroids and antibiotics. Studies suggesting that the pathophysiology of these disorders relates to a disregulated, over-active immune response to indigenous bacteria have led to the increasing importance of immunosuppressive drugs for the therapy of IBD. This review details the mechanisms of action, clinical efficacy, and adverse effects of these agents.
Talia Zenlea, Center for Women's Gastrointestinal Medicine, The Women's Medicine Collaborative, Alpert Medical School, Brown University, Providence, RI 02912, United States.
Talia
T
Zenlea
Talia Zenlea, Center for Women's Gastrointestinal Medicine, The Women's Medicine Collaborative, Alpert Medical School, Brown University, Providence, RI 02912, United States.
Mark A
MA
Peppercorn
D001688:Biological Products / Q000627:therapeutic use; D003093:Colitis, Ulcerative / Q000276:immunology / Q000628:therapy; D003424:Crohn Disease / Q000276:immunology / Q000628:therapy; D004359:Drug Therapy, Combination; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000276:immunology* / Q000628:therapy*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D001688:Biological Products; D007155:Immunologic Factors; D007166:Immunosuppressive Agents; D014409:Tumor Necrosis Factor-alpha
Crohn’s disease; Immunosuppressives; Inflammatory bowel disease; Tumor necrosis factor inhibitors; Ulcerative colitis